In early July, Merck announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add Verona's Ohtuvayre, approved for the maintenance treatment of chronic obstructive pulmonary disease. This addition will strengthen Merck's cardio-pulmonary pipeline and portfolio as the drug's differentiated profile provides a significant edge over its competitors.